Back to results
US 7,452,876 B2Granted
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
AssigneeBristol-Myers Squibb Company
InventorsKap-Sun Yeung, Katharine A. Grant-Young, Min Ding, Robert G. Gentles, John F. Kadow
Life of this patent
Estimating the term…
Abstract
The invention encompasses compounds as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
Claims14
A compound of formula I
- where:
- R1 is CO2R5 or CONR6R7;
- R2 is N(R10)(R11);
- R3 is hydrogen, halo, alkyl, alkenyl, hydroxy, benzyloxy, alkoxy, or haloalkoxy;
- R4 is cycloalkyl;
- R5 is hydrogen or alkyl;
- R6 is hydrogen, alkyl, alkylSO2, cycloalkylSO2, haloalkylSO2, (R7)(R8)NSO2, or (R9)SO2;
- R7 is hydrogen or alkyl;
- R8 is hydrogen or alkyl;
- R9 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperidinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from alkyl and alkoxy;
- R10 is hydrogen, alkyl, alkoxyCO, or (R12)(R13)NCO;
- R11 is hydrogen or alkyl;
- R12 is hydrogen, alkyl, alkoxyalkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R14)alkyl, (CON(R15)(R16))alkyl, or (tetrahydropyranyl)alkyl;
- R13 is hydrogen, alkyl, alkoxyalkyl, aminoalkyl, (alkylamino)alkyl, or (dialkylamino)alkyl;
- or (R12)(R13)N taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperidinyl, or homomorpholinyl and is substituted with 0-3 substituents selected from alkyl and alkoxy;
- R14 is hydrogen or alkyl;
- R15 is hydrogen or alkyl;
- and
- R16 is hydrogen or alkyl;
- or
- N(R15)(R16) taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperidinyl, or homomorpholinyl and is substituted with 0-3 substituents selected from alkyl and alkoxy;
- or a pharmaceutically acceptable salt thereof.
19 more elements
Dependencies are inferred from the claim text.